Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arbutus Biopharma Corp.

www.arbutusbio.com

Latest From Arbutus Biopharma Corp.

Deal Watch: Alexion Encouraged By RNAi Developments, Partners With Dicerna

Alexion thinks Dicerna’s RNAi technology could address complement-mediated conditions further upstream from antibodies like Soliris. AbbVie takes over CF collaboration with Galapagos, paying $45m up front.

Deals Business Strategies

Roivant Unveils An Autoimmune-Focused 'Vant' At Inaugural Pipeline Day

Immunovant is Roivant's 10th drug development-focused firm, progressing RVT-1401, an antibody targeting neonatal Fc receptor (FcRn) in immunoglobulin-mediated autoimmune diseases. Roivant showcased the budding pipeline of its growing family of companies, which now has 12 "vants."

Business Strategies Companies

BioNTech Signs Rare Disease Co-Development Deal With Genevant & Licenses LNP Platform

BioNTech and Genevant have boosted their clinical ambitions by agreeing a 50/50 co-development, co-commercialization collaboration for five mRNA rare disease programs. BioNTech also secured exclusive licenses to Genevant's LNP drug delivery platform for five oncology programs.

ImmunoOncology Personalized Medicine

Arcturus Founder Reinstated As CEO As Settlement Ends Four-Month Feud With Former Board

The unexpected firing of Arcturus CEO Joseph Payne kicked off a bitter public battle for control of the RNA therapeutics firm after a reverse merger with Alcobra in November. The dispute now settled, the new board has reinstated Payne at Arcturus' helm.

Legal Issues Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Liposomes
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Tekmira Pharmaceuticals Corp.
  • Inex Pharmaceuticals Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Arbutus Biopharma Corp.
  • Senior Management
  • Mark J Murray, PhD, Pres. & CEO
    Peter Lutwyche , PhD, CTO
    Michael J Sofia, PhD, CSO
    William T Symonds, PharmD, Chief Dev. Officer
  • Contact Info
  • Arbutus Biopharma Corp.
    Phone: (604) 419-3200
    100-8900 Glenlyon Pkwy.
    Burnaby, V5J 5J8
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register